These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23956952)

  • 41. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The diagnostic value of tumor biomarkers for detecting hepatocellular carcinoma accompanied by portal vein tumor thrombosis.
    Liu Y; Wang X; Jiang K; Zhang W; Dong J
    Cell Biochem Biophys; 2014 Jul; 69(3):455-9. PubMed ID: 24500835
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Application of classification tree and neural network algorithms to the identification of serological liver marker profiles for the diagnosis of hepatocellular carcinoma.
    Poon TC; Chan AT; Zee B; Ho SK; Mok TS; Leung TW; Johnson PJ
    Oncology; 2001; 61(4):275-83. PubMed ID: 11721174
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma.
    Liu C; Xiao GQ; Yan LN; Li B; Jiang L; Wen TF; Wang WT; Xu MQ; Yang JY
    World J Gastroenterol; 2013 Mar; 19(11):1811-9. PubMed ID: 23555170
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis.
    Salem R; Lewandowski R; Roberts C; Goin J; Thurston K; Abouljoud M; Courtney A
    J Vasc Interv Radiol; 2004 Apr; 15(4):335-45. PubMed ID: 15064336
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The effects of different clinicopathologic variables on serum protein fingerprint in hepatocellular carcinoma patients].
    Huang C; Fan J; Zhou J; Liu YK; Cui JF
    Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):445-9. PubMed ID: 16772076
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection.
    Fu YP; Yi Y; Huang JL; Jing CY; Sun J; Ni XC; Lu ZF; Cao Y; Zhou J; Fan J; Qiu SJ
    Oncologist; 2017 May; 22(5):561-569. PubMed ID: 28438885
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Significance of plasma osteopontin in diagnosis of hepatitis C virus-related hepatocellular carcinoma.
    Nabih MI; Aref WM; Fathy MM
    Arab J Gastroenterol; 2014; 15(3-4):103-7. PubMed ID: 25249230
    [TBL] [Abstract][Full Text] [Related]  

  • 49. AFP computational secreted network construction and analysis between human hepatocellular carcinoma (HCC) and no-tumor hepatitis/cirrhotic liver tissues.
    Wang L; Huang J; Jiang M; Zheng X
    Tumour Biol; 2010 Oct; 31(5):417-25. PubMed ID: 20532728
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis.
    Kuo YH; Wu IP; Wang JH; Hung CH; Rau KM; Chen CH; Kee KM; Hu TH; Lu SN
    Invest New Drugs; 2018 Apr; 36(2):307-314. PubMed ID: 28466374
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Folate levels in hepatocellular carcinoma patients with portal vein thrombosis.
    Malaguarnera G; Catania VE; Latteri S; Borzì AM; Bertino G; Madeddu R; Drago F; Malaguarnera M
    BMC Gastroenterol; 2020 Nov; 20(1):375. PubMed ID: 33172390
    [TBL] [Abstract][Full Text] [Related]  

  • 52. C-reactive protein and hepatocellular carcinoma: analysis of its relationships to tumor factors.
    Carr BI; Akkiz H; Guerra V; Üsküdar O; Kuran S; Karaoğullarından Ü; Tokmak S; Ballı T; Ülkü A; Akçam T; Delik A; Arslan B; Doran F; Yalçın K; Altntaş E; Özakyol A; Yücesoy M; Bahçeci Hİ; Polat KY; Ekinci N; Şimşek H; Örmeci N; Sonsuz A; Demir M; Kılıç M; Uygun A; Demir A; Yilmaz S; Tokat Y
    Clin Pract (Lond); 2018; 15(Spec Issue):625-634. PubMed ID: 29951199
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation.
    Piscaglia F; Gianstefani A; Ravaioli M; Golfieri R; Cappelli A; Giampalma E; Sagrini E; Imbriaco G; Pinna AD; Bolondi L;
    Liver Transpl; 2010 May; 16(5):658-67. PubMed ID: 20440775
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Circulating AFP mRNA as a Possible Indicator of Hematogenous Spread of HCC Cells: A Possible Association with HBV Infection.
    Montaser LM; Abbas OM; Saltah AM; Waked IA
    J Egypt Natl Canc Inst; 2007 Mar; 19(1):48-60. PubMed ID: 18839035
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatocellular carcinoma presenting as an incidental isolated malignant portal vein thrombosis.
    Poddar N; Avezbakiyev B; He Z; Jiang M; Gohari A; Wang JC
    J Gastrointest Cancer; 2012 Sep; 43(3):486-9. PubMed ID: 21190093
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The detection of circulating hepatocellular carcinoma cells in peripheral venous blood by reverse transcription-polymerase chain reaction and its clinical significance].
    Liu Y; Zhang B; Qian G; Chen H; Wu M; Fu J; Huang C
    Zhonghua Wai Ke Za Zhi; 1998 Oct; 36(10):608-10. PubMed ID: 11825477
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein.
    Oka H; Saito A; Ito K; Kumada T; Satomura S; Kasugai H; Osaki Y; Seki T; Kudo M; Tanaka M;
    J Gastroenterol Hepatol; 2001 Dec; 16(12):1378-83. PubMed ID: 11851836
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [A case of multiple hepatocellular carcinoma with rapidly progressing bilateral portal vein tumor thrombosis--a complete remission achieved with dual treatment of reductive surgery plus percutaneous isolated hepatic perfusion].
    Tsuchida S; Fukumoto T; Tominaga M; Iwasaki T; Kusunoki N; Sugimoto T; Kido M; Takebe A; Tanaka M; Hisoka K; Ku Y
    Gan To Kagaku Ryoho; 2005 Oct; 32(11):1818-20. PubMed ID: 16315951
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A hypothesis on paradoxical privileged portal vein metastasis of hepatocellular carcinoma. Can organ evolution shed light on patterns of human pathology, and vice versa?
    Subbotin VM
    Med Hypotheses; 2019 May; 126():109-128. PubMed ID: 31010487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.